The Association of Lunula Status With the Efficacy and Safety of Neoadjuvant Therapy in Breast Cancer

This is a multicentre study to investigate the association of fingernail lunula status with the efficacy and safety of neoadjuvant therapy in breast cancer patients.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Breast Cancer Invasive

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Renji Hospital, School of Medicine, Shanghai Jiaotong University

Shanghai, 200127, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Aged 18 years or older
Pathologically confirmed invasive primary breast cancer
Patients who have received or are scheduled to receive neoadjuvant therapy

Exclusion criteria

De novo stage IV breast cancer

Treatment and study plan

neoadjuvant therapy

Drug

patients receiving neoadjuvant therapy

Primary outcomes

Pathological Complete Response (pCR) Rate

Time frame: at surgery

ypT0 ypN0

Secondary outcomes

Disease-free Survival

Time frame: From surgery until time of event up to 8 years

Disease-free survival time is defined as the time from date of randomization until the first occurrence of disease recurrence, distant metastasis and death from any cause.

Sponsors and collaborators

Lead sponsor

Wenjin Yin

Other

Registry information

Important dates

Study start: 2026
Primary completion: 2031
Study completion: 2033
First posted: May 15, 2026
Registry last updated: May 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting